TRV GP III LLC
Q1 2020 Form 13-F
BOSTON, MASSACHUSETTS
CIK 0001637299
· Institutional investment manager
Consolidated report · includes
1 manager
since Q1 2018
$367.6M Reported Value Total
Reported value
$367.6M
Quarter over quarter
-25.0%
Holdings
5
Top-10 concentration
100.0%
Filing Structure
Reports holdings for
- Robert I. Tepper (not a 13F filer in our records) · File #028-18419 · since Q1 2018 · declared by one filing
- Mark Levin (not a 13F filer in our records) · File #028-18439 · Q1 2018 – Q3 2022 · declared by one filing
- STARR KEVIN P (not a 13F filer in our records) · File #028-18438 · Q4 2017 – Q4 2017 · declared by one filing
- Kevin P. Starr (not a 13F filer in our records) · Q4 2017 – Q4 2017 · declared by one filing
- Mark Levin (not a 13F filer in our records) · Q4 2017 – Q4 2017 · declared by one filing
- Robert I. Tepper (not a 13F filer in our records) · Q4 2017 – Q4 2017 · declared by one filing
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Kevin Gillis
Chief Operating Officer
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2020 13F record
Q1 2020 13F filing summary
| Period of report | March 31, 2020 |
|---|---|
| Filed | May 11, 2020 |
| Form | 13F-HR |
| Reported value | $367.6M |
| Positions | 5 |
| Change in reported value | +62.3% |
| New positions | 1 |
| Exited positions | 0 |
| Position turnover | 20.0% |
| Top-10 concentration | 100.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q4 2023 13F
Filed Feb 14, 2024
|
1 | $6.1M |
|
Q3 2023 13F
Filed Nov 13, 2023
|
1 | $5.9M |
|
Q2 2023 13F
Filed Aug 10, 2023
|
2 | $18.2M |
|
Q1 2023 13F
Filed May 12, 2023
|
3 | $83.0M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
5 | $127.6M |
|
Q3 2022 13F
Filed Nov 3, 2022
|
6 | $229.0M |
|
Q2 2022 13F
Filed Aug 12, 2022
|
7 | $244.5M |
|
Q1 2022 13F
Filed May 10, 2022
|
7 | $368.5M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
7 | $399.6M |
|
Q3 2021 13F
Filed Nov 5, 2021
|
7 | $526.8M |
|
Q2 2021 13F
Filed Aug 11, 2021
|
7 | $572.8M |
|
Q1 2021 13F
Filed May 12, 2021
|
7 | $790.6M |
|
Q4 2020 13F
Filed Feb 16, 2021
|
7 | $1.2B |
|
Q3 2020 13F
Filed Nov 6, 2020
|
7 | $1.2B |
|
Q2 2020 13F
Filed Aug 7, 2020
|
5 | $685.2M |
|
Q1 2020 13F
Filed May 11, 2020
|
5 | $367.6M |
|
Q4 2019 13F
Filed Feb 5, 2020
|
4 | $226.5M |
|
Q3 2019 13F
Filed Nov 4, 2019
|
4 | $176.5M |
|
Q2 2019 13F
Filed Aug 6, 2019
|
3 | $235.2M |
|
Q1 2019 13F
Filed May 3, 2019
|
3 | $204.2M |
5 earlier quarters on file — choose one from the quarter menu above.
Top 5 holdings · Q1 2020
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | RVMD REVOLUTION MEDICINES, INC. | $197.7M | 53.79% |
| 2 | FULC FULCRUM THERAPEUTICS, INC. | $71.2M | 19.37% |
| 3 | VYGR VOYAGER THERAPEUTICS, INC. | $58.5M | 15.91% |
| 4 | NTGN NEON THERAPEUTICS, INC. | $25.7M | 7.0% |
| 5 | JNCE JOUNCE THERAPEUTICS, INC. | $14.5M | 3.94% |
Values as reported on the Q1 2020 Form 13F. Every position is in the holdings table below.